gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Improvement of prognosis of invasive ovarian cancer since 1988, especially in patients younger than 65 years of age: results of the Munich Cancer Registry

Meeting Abstract

Suche in Medline nach

  • corresponding author presenting/speaker Gabriele Hölscher - Tumorregister München am Tumorzentrum München, IBE, LMU, München, Deutschland
  • Jutta Engel - Tumorregister München am Tumorzentrum München, IBE, LMU, München
  • Dieter Hölzel - Tumorregister München am Tumorzentrum München, IBE, LMU, München

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocOP338

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk448.shtml

Veröffentlicht: 20. März 2006

© 2006 Hölscher et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: Ovarian cancer treatment has advanced in the last 20 years. The purpose of this study was to determine whether survival has improved in line with treatment advances in a population-based prospective cohort of ovarian cancer patients.

Patients and Methods: Details of all cancer patients in the Munich region are recorded by the Munich Cancer Registry. Ovarian cancer patients with an invasive single tumour diagnosed between 1978 and 2002 were included in this analysis (n=2.800). Overall and stage-specific relative survival is available for all patients and patients younger than 65 years of age. The impact of age, FIGO-stage, histological type, and grade, chemotherapy, and debulking surgery was examined in a Cox regression model.

Results: The 5- and 10-year relative survival rates of the cohort of all cancer patients diagnosed after 1988 were noticeably higher than of those diagnosed before 1988 (5- / 10-year relative survival rates before (n=763) and after 1988 (n=1962): 35.0% / 27.0% versus 41.6% / 31.7%). In patients below 65 years of age the improvement in survival was even higher: 41.4% / 32.2% and 52.0% / 42.3% 5- and 10-year relative survival rates before (n=480) and after 1988 (n=1065). In terms of stage FIGO I to FIGO III patients of the whole sample showed an absolute improvement of 16.3% / 15.9% (FIGO I), 12.4% (10-year relative survival not reached, FIGO II) and 10.5% / 6.6% (FIGO III) of the 5- and 10-year relative survival rate, respectively. In FIGO IV patients were only seen a prolongation in the median survival time. The cohort of younger patients demonstrated a similar pattern (absolute improvements of the 5- and 10-year relative survival rates: FIGO I 19.2% and 19.3%, FIGO II 14.3% (10-year relative survival not reached), FIGO III 11.6% and 10.3%, and FIGO IV no improvement). The results of the Cox Analysis show a Relative Risk (RR) of 0.3 for a radical operation and a RR of 0.5 for chemotherapy after 1988. The results of the younger patients are comparable.

Conclusions: The improvements in survival may be due to more accurate staging especially in FIGO I and II patients (‘pseudo-effect’), but mostly to advances in treatment like more effective chemotherapy and more radical surgery (real improvement).